定义生存流行病学:针对患病者的诊断后人群科学
本文提出并正式定义「生存流行病学」这一新分支,聚焦已确诊疾病人群如何活得更长更好。作者通过跨心血管、肾脏、肿瘤、肺和肝脏疾病的概念与方法学评论,整合因果推断与时间事件分析原理,论证预防性估计不应假设适用于诊断后人群。
要点
- 诊断是因果阈值,改变时间尺度与偏倚结构,包括条件于疾病(碰撞分层)、时间依赖混杂、不死时间偏倚和反向因果。
- 诊断后可信推断需模拟随机试验的设计、明确时间零点与临床决策点对齐、按实际使用定义策略,并处理竞争风险、多状态转移和纵向生物标志物。
- 推荐对同一暴露-疾病对平行估计预防效应与诊断后生存效应,并按分期、亚型、治疗路径和诊断后时间常规报告异质性。
核心结论
- 预防与诊断后生存是不同的推断目标。
- 期刊应要求明确声明所涉为预防还是生存并报告目标试验要素;指南机构在证据允许时应区分预防与生存推荐;资助方、培训项目和公共传播应支持以生存为重点的方法、数据标准和针对患病者的情境化信息。
研究设计与样本
- 概念与方法学评论,综合心血管、肾脏、肿瘤、肺和肝脏疾病的证据,并整合因果推断与时间事件分析原理以回答诊断后问题。
主要发现
- 跨疾病来看,为发病率测量的关联在已确诊患者中常无法重现,有时方向相反。
- 诊断作为因果阈值改变时间尺度和偏倚结构,包括条件于疾病(碰撞分层)、时间依赖混杂、不死时间偏倚和反向因果。
- 诊断后可信推断需要模拟随机试验的设计、明确将时间零点与临床决策点对齐、按实际使用定义策略,并处理竞争风险、多状态转移和纵向生物标志物(适当时包括联合模型)。
- 必要的诊断后数据包括分期、分子亚型、既往治疗线数、剂量强度和调整、不良事件、体能状态和患者报告结局。
关键数值与推荐
- 推荐实践为对同一暴露-疾病对平行估计预防效应与诊断后生存效应,并按分期、亚型、治疗路径和诊断后时间常规报告异质性。
临床怎么用
- 作者认为期刊应要求明确声明所涉为预防还是生存并报告目标试验要素。
- 作者认为指南机构在证据允许时应区分预防与生存推荐。
- 作者认为资助方、培训项目和公共传播应支持以生存为重点的方法、数据标准和针对患病者的情境化信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Epidemiology is largely organized to explain who becomes ill, yet many clinical and public health decisions occur after diagnosis. I introduce and formally define survival epidemiology as a new branch of science focused on assessing how people live longer and better with established disease, and I provide justification that prevention estimates should not be assumed to apply postdiagnosis. STUDY DESIGN AND SETTING: Conceptual and methodological commentary synthesizing evidence across cardiovascular, renal, oncologic, pulmonary, and hepatic conditions and integrating causal-inference and time-to-event principles for postdiagnosis questions. RESULTS: Across diseases, associations measured for incidence often fail to reproduce, and sometimes reverse, among patients with established disease. Diagnosis acts as a causal threshold that changes time scales and bias structures, including conditioning on disease (collider stratification), time-dependent confounding, immortal time bias, and reverse causation. Credible postdiagnosis inference requires designs that emulate randomized trials; explicit alignment of time zero with clinical decision points; strategies defined as used in practice; and handling of competing risks, multistate transitions, and longitudinal biomarkers (including joint models when appropriate). Essential postdiagnosis data include stage, molecular subtype, prior therapy lines, dose intensity and modifications, adverse events, performance status, and patient-reported outcomes. Recommended practice is parallel estimation of prevention and postdiagnosis survival effects for the same exposure-disease pairs and routine reporting of heterogeneity by stage, subtype, treatment pathway, and time since diagnosis. CONCLUSION: Prevention and postdiagnosis survival are distinct inferential targets. Journals should require clarity on whether claims pertain to prevention or survival and report target-trial elements; guideline bodies should distinguish prevention from survival recommendations when evidence allows; and funders, training programs, and public communication should support survival-focused methods, data standards, and context-specific messaging for people living with disease.
引用
- Cuomo RE. Defining survival epidemiology: postdiagnosis population science for people living with disease. J Clin Epidemiol. 2025. PMID: 41461361. doi:10.1016/j.jclinepi.2025.112122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。